Clin2
NCT07120464Likely a fitRecruiting

Rabies vaccine study for people with weak immune systems or older age

Rabies ExposureImmunocompromisedChronic Disease

Part of Immune system & allergy, Infections clinical trials.

This study tests how well a rabies vaccine works and how safe it is for people whose immune systems may be weaker, such as those with certain long-term illnesses, organ transplants, or age 60 and older. It compares them to healthy adults ages 18 to 59.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
180 people
Ages
Any age
Study type
Observational

Who can take part

  • You must have been exposed to rabies (Category II or III) and need the vaccine after exposure.
  • If you are age 18 to 59 and healthy, you can join the control group.
  • If you have long-term immune system problems (like certain cancers, autoimmune diseases, or organ transplants), you may join the study group.
  • If you have diabetes, chronic hepatitis, liver cirrhosis, kidney disease, or are age 60 or older, you may also join the study group.
  • You must agree to follow the study schedule and sign a consent form.
  • You cannot have had a rabies vaccine before or have HIV.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07055880Not yet recruiting· Phase 2
Rabies vaccine doses for adults 18 to 59

This trial tests different doses of a rabies vaccine to see how well they protect against rabies and how safe they are. It's for healthy adults who may need rabies protection, for example after an animal bite or as routine prevention.

Karachi
NCT07338786Enrolling by invitation· Phase 1
Rabies vaccine safety trial for ages 10 to 60

This trial tests a freeze-dried rabies vaccine to see how safe it is when given on different schedules. It may be an option for people who need protection from rabies.

Xuzhou, Jiangsu
NCT07455318Not yet recruiting· Phase 3
Rabies vaccine booster after pre-exposure doses

This study tests whether a single booster dose of the rabies vaccine is still effective in people who received the primary pre-exposure series several years ago. It compares three different vaccine regimens to see which one boosts immunity best.

Antwerp
NCT07500207Enrolling by invitation· Phase 3
Rabies vaccine trial for people aged 10 to 60

This trial tests a new lyophilized rabies vaccine to see how well it works and how safe it is. It is for people who have not been vaccinated against rabies recently and have not been bitten or scratched by an animal that broke the skin in the past year.

Neijiang, Sichuan
NCT07055893Not yet recruiting· Phase 3
Rabies vaccine for preventing infection after exposure

This study tests a new rabies vaccine given after a possible exposure to rabies (like a bite) to see how well it works and how safe it is. The vaccine is given in a series of shots to help your body fight the rabies virus.

Rawalpindi
NCT07028801Not yet recruiting· Phase 3
New rabies vaccine for people ages 10 to 60

This trial tests a new freeze-dried rabies vaccine grown in human cells. It aims to confirm the vaccine is safe and works well for people aged 10 to 60 who have not been vaccinated against rabies before and have not been recently bitten by a rabid animal. By joining, you help ensure that a reliable vaccine is available to protect against this serious disease.

Zhengzhou, Henan

Hear when a new Immunocompromised trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.